CABLIVI

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Estonia, Finland, France, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug CABLIVI contains one active pharmaceutical ingredient (API):

1	Caplacizumab UNII 2R27AB6766 - CAPLACIZUMAB
	Caplacizumab is a humanised bivalent Nanobody that consists of two identical humanised building blocks (PMP12A2hum1), genetically linked by a three-alanine linker, targeting the A1-domain of von Willebrand factor and inhibiting the interaction between von Willebrand factor and platelets. As such, caplacizumab prevents the ultralarge von Willebrand factor-mediated platelet adhesion, which is characteristic of aTTP. It also affects the disposition of von Willebrand factor, leading to transient reductions of total von Willebrand factor antigen levels and to concomitant reduction of factor VIII:C levels during treatment.
	Read more about Caplacizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CABLIVI Powder and solvent for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AX07		B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AX Other antithrombotic agents
Discover more medicines within B01AX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	576721090096401
CA	Health Products and Food Branch	02496194
EE	Ravimiamet	1779015, 1802517
ES	Centro de información online de medicamentos de la AEMPS	1181305001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	067273
FR	Base de données publique des médicaments	64183564
GB	Medicines & Healthcare Products Regulatory Agency	377580
IL	מִשְׂרַד הַבְּרִיאוּת	8499
JP	医薬品医療機器総合機構	3399415D1027
LT	Valstybinė vaistų kontrolės tarnyba	1086199, 1086755, 1087361
NL	Z-Index G-Standaard, PRK	197416
PL	Rejestru Produktów Leczniczych	100410686
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65588001, W65588002, W65588003
US	FDA, National Drug Code	58468-0225, 58468-0227, 58468-0229